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Abstract
SIGNALING THROUGH HOMOMERIC AND HETEROMERIC CANNABINOID CB1
RECEPTORS
By Guoqing Xiang B.S.

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2018

Advisor: Professor Diomedes E. Logothetis Ph.D.

Cannabis (Marijuana) has multiple effects on the human body, such as analgesia, euphoria and
memory impairment. Delta-9 tetrahydrocannabinol (∆9-THC), the active ingredient in cannabis,
binds to cannabinoid receptors, seven-transmembrane G protein-coupled receptors (GPCRs) that
mediate a variety of physiological functions. GPCRs were believed to function only in
homomeric forms, however, recent findings show that different GPCRs can also form
heteromeric complexes that may expand their signaling properties. In this study, we focused on
Cannabinoid CB1 receptor (CB1R) heteromers with the mu-opioid receptor (MOR) and the
Dopamine type 2 receptor (D2R), respectively. We utilized a variety of techniques, such as the
calcium mobilization assay, a luciferase complementation assay and an electrophysiology assay
to study the pharmacology of the CB1R-MOR and CB1R-D2R heteromers. Our data

xi

demonstrate that co-expression of CB1R enhances the Gi signaling through MOR and inhibits
the beta-arrestin recruitment to MOR. We also show that co-application of CB1R ligands can
further accentuate the MOR signaling modulation. Co-expression of a CB1R transmembrane
domain 5 (TM5), but not a TM1, mini-gene abrogated the signaling change suggesting that it is
likely due to heteromerization of MOR and CB1R. Utilizing this herteromeric signaling could
provide a novel therapeutic approach that may yield potent analgesic effects with reduced side
effects. We have also found that CB1R switched its signaling specificity from Gi to Gs upon its
heteromerizaiton with D2R. In conclusion, our data show that CB1R expands its signaling
repertory and modulates the partner receptor signaling upon heteromerization.

xii

Chapter 1 INTRODUCTION

1.1 G protein-coupled receptor signaling
1.1.1

G protein signaling
G protein-coupled receptors (GPCRs) play critical roles in physiology and pathophysiology

and nearly half of the drugs on the market are targeting GPCRs. All GPCRs possess seven
transmembrane (TM) domains with an extracellular N- and intracellular C-terminus on either end
connected by six loops (three intracellular and three extracellular) (Lefkowitz 2004). GPCRs are
classified into six families, A through F, based on their amino acid sequences and functional
similarities (Hu et al 2017). The class A GPCR family, also called rhodopsin-like family, is the
largest group including neurotransmitter, hormone and light receptors. Class B, is also referred to
as the “secretin receptor family”. Class C includes the metabotropic glutamate, GABA and taste
receptor family, which characterized by a large extracellular N-terminal domain where the ligand
binds, unlike with members of the other classes that possess their binding site within the
transmembrane domains. Class D includes fungal mating pheromone receptors, Class E includes
cAMP receptors and Class F contains the frizzled /smoothened receptors (Hu et al 2017). All the
receptors of interest in this dissertation (CB1R, MOR and D2R) belong to Class A receptors.
GPCRs transduce extracellular stimuli into intracellular signaling events mainly through
signaling that involves heterotrimeric G proteins which consist of three subunits: Gα, Gβ and
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Gγ. There are 16 subtypes of Gα, 5 subtypes of Gβ and 14 subtypes of Gγ (Milligan et al. 2006).
Gα was believed to play the major role in mediating different signals grouped into Gs (including
Gs and Golf), Gi (including Gi1-3, Go, Gt1/2, Ggust and Gz), Gq (including Gq, G11, G14-16)
and G12/13 (including G12 and G13) (Milligan et al. 2006). Gs was named so as it stimulates
adenylate cyclase (AC) leading to an increase in intracellular cAMP level, whereas Gi was
named so as it inhibits AC and therefore decreases cAMP levels (Preininger et al 2004). The Gq
superfamily directly interacts and activates Phospholipase C (PLC) that hydrolyzes
Phosphatidylinositol 4, 5-biphosphate (PIP2) into diacylglycerol (DAG) and inositol 1, 4, 5triphosphate (IP3) (Preininger et al 2004). IP3 opens IP3 channels on the endoplasmic reticulum
(ER) resulting in intracellular calcium mobilization from the ER to the cytosol. Gβ and Gγ,
which form obligatory dimers, were found to also mediate signaling such as the activation of G
protein sensitive inwardly rectified potassium channels (GIRK) and the inhibition of N-type
voltage-gated calcium channels (Milligan et al. 2006).
The molecular mechanism underlying GPCR activation has been widely studied. A GPCR is
in an “inactive” conformation when no ligand is bound to it and the G protein α subunit (Gα) is
bound to guanine diphosphate (GDP) forming a complex with the G protein βγ subunits. Once
the ligand binds to the receptor, it promotes the GPCR change to an active conformation which is
transmitted to the associated Gα subunit causing an increase in its affinity to guanine
triphosphate (GTP). The activated Gα dissociates from Gβγ and interacts with its downstream
effectors, such as AC or PLC. Hydrolysis of GTP to GDP allows Gα to undergo a
conformational rearrangement back to the inactive form and to complex with the βγ subunits.
This G protein cycle is shown in Figure 1.1.
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Ligands are divided into four groups based on their effects on G protein signaling: full
agonist, partial agonist, neutral antagonist and inverse agonist. As shown in Figure 1.2, a full
agonist activates the receptor and produces the maximum biological response, while a partial
agonist also activates the receptor but produces a response lower than that of the full agonist
(partial efficacy relative to that of a full agonist) (Rosenbaum et al 2009). A neutral antagonist
binds to the receptor but does not produce any biological response, while an inverse agonist
produces the response that is opposite to that of an agonist (Rosenbaum et al 2009). Both neutral
antagonists and inverse agonists are able to block the effects of agonists.

1.1.2

Arrestin signaling
G protein signaling is not the only signaling pathway that mediates GPCR biological

responses. GPCR activation also recruits the intracellular protein arrestin leading to a variety of
signaling cascades. Arrestin proteins are classified into four categories: arrestin-1 (also named
visual or rod arrestin), arrestin-2 (also called beta-arrestin or beta-arrestin1), arrestin-3 (betaarrestin2) and arrestin-4 (cone or X-arrestin) (Gurevich et al. 2014). Arrestin 1 and 4 are almost
exclusively expressed in the visual system, whereas arrestin 2 and 3 (beta-arrestins) are found to
be present throughout the central nervous system (CNS) (Gurevich et al. 2014). Upon GPCR
activation, released Gβγ further activates G protein receptor kinase (GRK) that phosphorylates
GPCR, which recruits beta-arrestins. Beta-arrestin binding to the receptor prevents the G protein
interaction and therefore desensitizes the GPCR. Other than desensitization, beta-arrestin also
causes GPCR internalization in a clathrin-dependent endocytosis manner (Lefkowitz et al. 2005).
Studies have shown that GPCR desensitization and internalization by beta-arrestin is critical for
certain drug side effects (Sim et al. 1996; Bohn et al. 1999).
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1.1.3

GPCR heteromerization
Although GPCRs were initially thought to function in monomeric forms, recent studies

have provided evidence for GPCR hetero-complexes. A widely accepted example of GPCR
heteromerization is with the GABAB receptor subtypes (GABAB-R1 and GABAB-R2). Studies
have shown that only the heterodimer forms a functional receptor and each of the protomers (R1
and R2) is unable to signal by itself (Bowery et al. 2000). Furthermore, heterodimerization of
GABAB is mediated by parallel coiled-coil C-terminal interactions (Calver et al. 2001).
Heteromerization of GPCR has been reported to alter a variety of signaling properties including
changes in binding properties, G protein activation, G protein specificity and beta-arrestin
signaling (Rozenfeld et al. 2011). Research has also suggested that GPCR heteromers are
involved in a number of physiological and pathophysiological processes and may serve as
potential drug targets. However, given a large number of studies investigating GPCR heteromers
which sometimes lead to opposing results, scientists in the field have set up criteria to help
establish a thorough and critical evaluation of studies on GPCR heteromers. These are:
Criterion 1: Heteromer components should co-localize and physically interact;
Criterion 2: Heteromer should exhibit properties distinct from those of the protomers;
Criterion 3: Heteromer disruption should lead to a loss of heteromer-specific properties (Gomes
et al. 2015).

1.2 The CB1R
1.2.1

Introduction
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Marijuana has been used for over 2000 years for medical as well as recreational purposes.
∆9-tetrahydrocannabinol (∆9-THC) was identified as the primary psycho-active ingredient in
cannabis. Later, two endogenous cannabinoids anandamide and 2-Arachidonoylglycerol (2-AG)
were found in the brain (Devane et al. 1992; Sugiura et al. 1995). The effects of ∆9-THC and
endogenous cannabinoids are mediated by cannabinoid receptors, that belong to the Class A
GPCR family (Devane et al. 1988). There are two classic types of cannabinoid receptors, CB1R
and CB2R. CB1R is primarily expressed in the brain and CB2R is predominantly found in the
immune system. CB1R is critical for mediating analgesia, reinforcement and other neuro-psycho
effects since CB1R knockout mice do not respond to cannabinoids (∆9-THC) (Ledent et al.
1999). Very recently, crystal structures of human CB1R in both inactive and active
conformations were solved in Raymond Stevens’ lab (Hua et al. 2016; Hua et al. 2017).

1.2.2

CB1R localization

Receptor localization is crucial to understanding its function. Herkenham et al first utilized
autoradiographic studies to show that CB1R was highly expressed in brain regions such as the
basal ganglia (lateral caudate-putamen, globus pallidus, substantia nigra pars reticulata)
cerebellar molecular layer, innermost layers of the olfactory bulb (Herkenham et al. 1991). The
localization of CB1R is consistent with psychoactive effects of ∆9-THC. Interestingly, CB1R
expression was very low in the respiratory centers of the medulla, which is also consistent with
the fact that cannabinoids do not cause respiratory depression. Later, a high resolution depiction
of the localization of CB1R provided by immunocytochemical studies showed that the receptor
is abundant on GABAergic axon terminals, which is in agreement with endocannabinoidmediated retrograde signaling (endocannabinoid synthesized at post-synapse travels “backward”
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to the pre-synapse to activate presynaptic CB1R and modulate neurotransmission) (Bodor et al.
2005).

1.2.3

CB1R signaling
CB1R primarily couples to the inhibitory G protein (Gi/o protein). Therefore, its activation

leads to inhibition of adenylyl cyclase, activation of G protein sensitive inwardly rectifying
potassium channels (GIRK) and inhibition of certain voltage-gated calcium channels. The
activation of potassium channels and the inhibition of calcium channels retard excitability,
causing analgesia and neuroprotective effects. Studies also show that CB1R activation recruits
beta-arrestin leading to receptor desensitization and internalization (Jin et al. 1999). Receptor
desensitization and internalization have been reported to be one of the molecular mechanisms
underlying tolerance development after chronic administration of cannabinoids (Nguyen et al.
2012).

1.2.4

Drugs targeting CB1R
There are several clinically available medications targeting on CB1R. Marinol

(Dronabinol), which is a synthetic form of ∆9-THC, is used as antiemetic for patients receiving
chemotherapy and an appetite stimulant. Marinol is available in some countries such as the US
and Canada. Cesamet (Nabilone) is also a synthetic cannabinoid with a structure similar to ∆9THC, used for the treatment of the nausea and vomiting associated with chemotherapy. Apart
from agonists at CB1R, inverse agonist at CB1R, Rimonabant (also known as SR141716), was
first approved in Europe as an anti-obesity drug but was withdrawn from the market two years
later due to psychiatric side effects (Sam et al. 2011).
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1.3 The MOR
1.3.1

MOR Introduction

Opioids, the active ingredients from the opium plant, are primarily used for the treatment of
pain. Morphine, one of the natural components in opium, has been used in the clinic for nearly
200 years. Despite the high effectiveness in analgesia, morphine has serious side effects such as
respiratory depression, dependence and constipation. The effects of opioids are mediated by G
protein-coupled receptors, opioid receptors. So far, three major classes of opioid receptors were
identified: mu-opioid receptor (MOR), kappa-opioid receptor (KOR) and delta-opioid receptor
(DOR) (Martin et al 1976; Cox et al 2015). Morphine has the highest affinity towards MOR and
MOR activation accounts for the analgesic effects as MOR knockout mice fail to respond to
morphine (Sora et al. 1997). High-resolution crystal structures of MOR in both the active and
inactive conformations have been recently solved in Brian Kobilka’s lab (Manglik et al 2012;
Huang et al 2015).

1.3.2

MOR localization
Opioid receptors are present in central as well as in peripheral neurons (Stein 2015). To

further understand the physiological roles of these receptors, neuroanatomical studies have found
that MOR is highly expressed in the caudate putamen and nucleus accumbens, consistent with
MOR’s role in pain perception (Peng et al 2012). In the spinal cord, ascending and descending
pathways are crucial in analgesia. MOR expression was found in the ascending pathway (Peng et
al 2012). MOR expression were also found in the peripheral nervous system (Bagnol et al. 1997).
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Regarding cellular and subcellular distributions, MOR localizes both at pre-synapse and postsynapse on various neurons (GABAergic, glutamatergic and cholinergic) (Chen et al 2015).

1.3.3

MOR signaling
MOR belongs to Gi/o protein-coupled receptor family. As a result, its activation leads to

cAMP inhibition and hyperpolarization of neurons due to activation of G protein sensitive
inwardly rectified potassium channels (GIRK) and inhibition of N-type voltage-gated calcium
channels (Stein 2015). In addition, studies also have pointed out that inhibition of transient
receptor potential vanilloid type 1 channels (TRPV1) by activation of MOR in dorsal root
ganglion (DRG) neurons plays crucial roles in inflammatory pain treatment (Endres-Becker et al.
2007). Apart from G protein signaling, which mainly mediates the analgesic effects of opioids,
MOR is also able to signal through the beta-arrestin pathway that is implicated in tolerance,
respiratory depression and constipation (Manglik et al. 2016). Thus, looking for compounds that
selectively activate the G protein pathway through MOR with a minimal beta-arrestin
recruitment (defined as “Biased signaling”) has become a hot topic in the GPCR field.

1.3.4

Drugs targeting MOR

MOR agonists such as Morphine, fentanyl, hydrocodone and oxycodone are commonly used
in the clinic as analgesics. However, the misuse and addiction of opioids has become not only a
public health issue but a social and economic welfare issue as well, given that more than 115
people die every day from opioid overdose in the United States according to reports from the
National Institute on Drug Abuse. TRV-130 (Oliceridine) developed by Trevena, which only
elicits G protein signaling through MOR with minimal beta-arrestin recruitment, may have fewer
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adverse effects than currently prescribed opioids. MOR antagonists, such as Naloxone, are also
used in the clinic to treat opioid overdose.

1.4 The D2R
1.4.1

D2R introduction

Dopamine in the brain modulates a variety of physiological processes such as voluntary
movement, mood, reward and cognition, which are mediated by five subtypes of dopamine
receptors (D1R, D2R, D3R, D4R and D5R) (Beaulieu et al. 2015). Dysregulation of
dopaminergic system is involved in a variety of neurological diseases such as Parkinson’s
disease, schizophrenia, addiction, depression and attention deficit hyperactivity disorder. D1R
and D5R (D1-class receptors) are primarily Gs-coupled receptors, whereas D2R, D3R and D4R
(D2-class receptors) are Gi-coupled receptors (Beaulieu et al. 2015) . The D3R and D2R crystal
structures have been determined (Wang S et al. 2018; Chien EY et al. 2010).

1.4.2

D2R localization

D2R has been found abundantly distributed in the striatum and substantia nigra, which
explains its role in voluntary motor control. D2R is also present at the nucleus accumbens and
the frontal cortex. The mesolimbic system pathway originates from the ventral tegmental area
(VTA) and projects to the nucleus accumbens and the mesocortical system originates from the
VTA and projects to the frontal cortex. Dopaminergic projections in both the mesolimbic and
mesocortical pathways play critical roles in reward, emotion, learning as well as executive
function. Studies using D2R-knockout mice showed that D2R is responsible for mediating motor
activity and learning and reward (Tran et al 2002).
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1.4.3

D2R signaling

D2R is primarily Gi-coupled receptor and its activation leads to inhibition of cAMP,
activation of G protein sensitive inwardly rectified potassium channels (GIRK) and inhibition of
certain voltage-gated calcium channels (Beaulieu et al. 2015). D2R at the presynaptic terminal
(also named “autoreceptors”) modulates neuron firing rate as well as dopamine release (Missale
et al. 1998). D2R has been reported to signal through Gq pathway upon heteromerization with
D1R (Rashid AJ, So CH et al. 2007). Besides G protein signaling pathway, D2R is also found to
recruit beta-arrestin which mediates desensitization and internalization (Beaulieu et al. 2015).

1.4.4

Drugs targeting D2R

There are a great number of drugs treating different diseases targeting D2R. For example, LDOPA, the most common treatment for Parkinson’s Disease, is a metabolic precursor of
dopamine. Chlorpromazine, the first generation of antipsychotic drug, is a D2R antagonist.

1.5 The CB1R-MOR heteromer
1.5.1

Co-localization of CB1R and MOR

Both the cannabinoid and opioid systems are involved in a number of physiological processes
like nociception and addiction. Furthermore, studies have shown that CB1R and MOR colocalize in the same neuron. Utilizing electron microscopic immunocytochemical labeling of
CB1R and MOR in GABAergic spiny neurons in the caudate putamen nucleus (CPN), colocalization of CB1R and MOR was confirmed in rat CPN (Rodriguez et al 2001). In addition,
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another study has shown that CB1R and MOR also co-localize in the rat spinal cord dorsal horn
(Salio et al 2001)

1.5.2

Synergism between cannabinoids and opioids

Early animal behavior studies have shown that a sub-functional dose of ∆9-THC (20mg/kg) in
combination of morphine significantly left shifts the ED50 of morphine from 28.8 to 13.1 mg/kg
in the tail-flick assay, suggesting an interesting interaction between the cannabinoid and opioid
systems (Figure 1.3) (Cichewicz et al. 1998). Furthermore, clinical studies have shown that
vaporized cannabis augmented the analgesic effects of morphine with little alterations in the
plasma opioid level, indicating that cannabinoids and opioids may work synergistically (Abrams
et al 2011). These phenomena motivate us to explore whether the synergism is mediated by the
CB1R-MOR heteromer.

1.5.3 Evidence of CB1R-MOR heteromer
Besides the co-localization of these two receptors mentioned above, Bioluminescence
resonance energy transfer (BRET) in heterologous expression systems has confirmed that MOR
and CB1R can be in close proximity when they are co-expressed in HEK293 cells (Rios et al
2006). Another evidence for CB1R-MOR heteromer is that treatment with a bivalent ligand
(MOR agonist linked with CB1R antagonist with a 20-atom spacer) leads to potent analgesic
effects with reduced tolerance (Le Naour et al 2013).

1.5.4 Therapeutic advantages targeting CB1R-MOR heteromer
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Opioids are the most common analgesics despite their side effects. Targeting the CB1R-MOR
heteromer will help to provide a novel target with three possible therapeutic advantages. Firstly,
given the synergistic interaction between cannabinoids and opioids, targeting the CB1R-MOR
heteromer with agonists will achieve strong analgesic effectiveness; Secondly, co-administration
of ∆9-THC decreases morphine tolerance, suggesting that targeting the CB1R-MOR may reduce
tolerance (Figure 1.3) (Cichewicz DL et al 2003). Thirdly, since CB1R is absent in the
respiratory centers in the medulla and CB1R and MOR co-localize in the caudate putamen
nucleus as well as in peripheral neurons, targeting the CB1R-MOR will circumvent the
respiratory depression side effects of opioids. Exploring the signaling through the CB1R-MOR
heteromeric complex will facilitate the development of novel analgesic therapeutics.

1.6 The CB1R-D2R heteromer
1.6.1

Co-localization of CB1R and D2R

Both CB1R and D2R are found to be present at the striatum. Hermann et al studied the
overlapping expression of CB1R and D2R using in situ hybridization on mouse brain sections.
They showed that in the striatum and the olfactory tubercle CB1R is co-expressed with D2R
(Hermann H et al. 2000). Electron microscopic immunocytochemistry further confirms the
subcellular locations of the CB1R and D2R in the nucleus accumbens, as Pickel et al found that
CB1R and D2R immunoreactivities overlapped at the labelled somata and dendrites (Pickel et al
2006).

1.6.2

Crosstalk between cannabinoid and dopamine system

12

Utilizing whole-cell patch clamp on mouse brain slices, D2R activation by quinpirole
decreases the excitatory transmission on striatal medium spiny neurons, whereas the decrease is
absent when the CB1R antagonist, AM251, was co-administrated or in CB1R-knockout mouse
brain slice (Yin HH et al 2006). This result suggests that CB1R-D2R interaction may play a role
in D2R effects on inhibition of glutamate release. Another study has found that D2R may
facilitate endocannabinoid signaling as the presence of a D2R agonist induces endocannabinoid
dependent long term depression of inhibitory transmission (Chiu et al 2010).

1.6.3

Evidence for CB1R-D2R heteromer
In vitro studies have found that CB1R and D2R can form receptor heteromers.

Co-immunoprecipitation (co-IP) suggests that CB1R and D2R could physically interact with
each other in HEK 293 cells expressing both receptors (Kearn et al. 2005). The CB1R-D2R
complex formation has been reported to be dynamic and peak formation occurs when both
receptors are simultaneously activated by their agonists (Kearn et al. 2005). Utilizing the
fluorescence resonance energy transfer (FRET) technique, Marcelline et al. found that
fluorescently tagged CB1R and D2R are in close proximity when they were co-expressed in
HEK 293 cells (Marcellino D, Carriba P et al. 2008).
The CB1R and D2R interaction has been reported to exhibit very unique signaling
properties. Glass M and Felder CC first reported that co-stimulation of CB1R and D2R increases
cAMP level in striatal neurons, suggesting that CB1R may possibly switch its G protein
signaling specificity from Gi to Gs (Glass M et al. 1997). Subsequently, Jarrahian A et al.
showed in HEK 293 cells, that only co-expression of D2R is sufficient to switch CB1R from Gicoupled to Gs-coupled (Figure 1.4) (Jarrahian A et al. 2004). In this dissertation work, we used
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electrophysiology and GIRK channels as reporters of GPCR signaling as well as a calcium
mobilization assay to study the signaling through the CB1R-D2R heteromeric complex.

1.6.4

Implications of CB1R-D2R heteromer
Since both CB1R and D2R are involved in learning and reward, CB1R-D2R heteromer

may play a critical role in drug abuse. CB1R-knockout mice showed less alcohol induced
conditioned place preference and more binding to D2R agonist quinpirole in the striatum
(Houchi et al. 2005). Interestingly, chronic alcohol treatment reverses the up-regulation of CB1R
in the cortex, caudate-putamen and nucleus accumbens in mice lacking D2R, suggesting a role of
CB1R-D2R heteromer in alcohol addiction (Thanos et al 2011). More research is needed in
order to better understand the role of the CB1R-D2R complex in physiology and
pathophysiology.
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Figure 1.1 G protein signaling Adopted from Preininger et al. 2004
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Figure 1.2 Different ligands at GPCR. Concepts of full agonist, partial agonist, neutral
antagonist and inverse agonist. Adopted from Rosenbaum et al. 2009
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Figure 1.3 THC enhances morphine analgesic effects and attenuates morphine tolerance. A.
THC enhances morphine analgesic effects. A sub-functional dose of ∆9-THC (20mg/kg) was
administered orally 15 min before morphine treatment. Tail-flick test was performed 30 min
later. B. THC attenuates morphine tolerance. Water vehicle, morphine (200mg/kg p.o. days 1-2;
300mg/kg p.o. days 3-7) or morphine plus 20 mg/kg ∆9-THC twice daily for 7 days was given to
mice to develop morphine tolerance. 12 h after the last drug administration, different
concentrations of morphine were given and tail-flick test was performed 30 min later. Figures
adopted from Cichewicz DL et al. 1998 and Cichewicz DL et al. 2003.

Morphine + THC
Morphine

B)
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Figure 1.4 CB1R can couple to Gs in the presence of D2R. cAMP assay was
performed in HEK 293 cells co-expressing CB1R and D2R. 10µM Forskolin (FSK),
10µM CP55,940 (CP), 1µM SR141716(SR) and 10µM Quinpirole (Quin) were used in
this experiment. Figures adopted from Jarrahian A et al. 2004
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CHAPTER 2
MATERIAL AND METHODS

2.1 Reagents
DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin), Dopamine, Morphine (solution in
methanol), CP55,940 were purchased from Sigma-Aldrich. WIN 55,212-2 was purchased from
Tocris. TRV130 (Oliceridine) was purchased from AdooQ Bioscience. SR141716 (Rimonabant)
and all the AM compounds were kindly provided by Dr. Alexandros Makriyannis’ lab at
Northeastern University. CP55,940, WIN55,212-2, SR141716 and all the AM compounds were
dissolved in DMSO at a 10mM stock concentration. DAMGO and Dopamine were dissolved in
DI water at a 10mM stock concentration.

2.2 Molecular Biology
The cDNA constructs used in Xenopus oocyte heterologous expression system were subcloned
into pGEM HE or pXOOM to enhance protein expression in oocytes. To transcribe DNA to
RNA, DNA was first linearized and purified (Pure Link PCR Purification kit, Thermo Fisher
Scientific). Transcription was done using mMESSAGE mMACHINE T7 Transcription Kit
(Thermo Fisher Scientific). The cDNA constructs used in mammalian cells were subcloned into
pcDNA3.1, pcDNA 3 or pXOOM to achieve optimal expression for the calcium mobilization
assay. The cDNA used for NanoBiT luciferase complementation assay was subcloned into Flexi
vectors provided by Promega. Mutations were introduced utilizing pfu-based mutagenesis
technique according to QuikChange mutagenesis kit protocol. All the sequence information was
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verified by GENEWIZ or Macrogene sequencing. Rat CB1 in pGEM HE DNA was kindly
provided by Dr. Ken Mackie at Indiana University. GCaMP 6s construct was a gift from Dr. Jose
M. Eltit at VCU.

2.3 Oocyte preparation and injection
Xenopus laevis frogs were maintained according to IACUC protocols at both Virginia
Commonwealth University and Northeastern University. Frogs were first anesthetized with
buffered Tricaine solution and ovarian tissue was taken out manually. The ovarian tissue was cut
into small pieces and digested in collagenase containing OR2 (-) solution 85mM NaCl, 5mM
HEPES, 5mM KCl, 1mM MgCl2, 1.8mM CaCl2, pH 7.5). After collagenase treatment, oocytes
were then washed in OR2 (-) and followed by OR2 (+) solution at room temperature. Oocytes
were finally incubated in OR2 (+) solution with 1% Penicillin and Streptomycin. Stage V and VI
oocytes were selected for microinjection of RNA ranging from 0.5 ng to 2 ng encoding proteins
of our interest (e.g. MOR, CB1R and GIRK1 and GIRK2) and incubated at OR2 (+) solution
with P/S for 24-60 h to allow optimal expression.

2.4 Two-electrode voltage clamp
Glass electrodes were first pulled by Flaming-Brown micropipette puller and then filled
with 1.5% agarose containing 3M KCl solution. Resistance of the electrodes was kept between
0.1 MΩ and 1.5 MΩ. A voltage ramp protocol was used to monitor inward rectification current,
from -80 mV towards +80 mV with a holding voltage at 0 mV. Current was recorded utilizing a
GeneClamp 500 amplifier (Axon Laboratories) or NPI TURBO TECH03 amplifier. G proteinsensitive inwardly rectifying K+ (GIRK) current was exhibited by perfusion of HK solution
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(96mM KCl, 5mM HEPES, 1mM MgCl2, 1mM NaCl, 1.8mM CaCl2, pH 7.5). 3mM Barium
Chloride (BaCl2) in HK solution was used at the end of the recording to block the GIRK current.

2.5 HEK293 cells culture and transfection
Human embryonic kidney (HEK293) cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin (P/S). Cells were always maintained at 37oC and 5% CO2 in cell incubator. To
obtain cell expression of CB1R and other proteins, we transiently transfected cells. For the
calcium mobilization assay, cells were first seeded into 96-well plate in OPTI-MEM (reduced
serum media) (ThermoFisher) with 5% FBS one day before transfection. On the day of
transfection, cells should have been around 50% to 90% confluent. DNA of interest and
transfection reagent (Lipofectamine 2000, Turbofect, Ecotransfect or PolyEthylenImine) was
pre-mixed in OPTI-MEM, before adding into cells seeded one day before. All the transfection
procedures were done according to the manufacturer’s instructions. The transfect medium was
changed into DMEM with 10% FBS and 1% P/S 12-24 hours after transfection. The calcium
mobilization assay was performed 24-48 hours post transfection. For the NanoBit luciferase
complementation assay, cells were transfected using Lipofectamine2000 according to the
manufacturer’s protocol 28 hours before the assay.

2.6 Calcium mobilization assay and luciferase complementation assay
For the calcium mobilization assay, cells that were transfected were changed into Hank’s
buffered salt solution (HBSS) one or two days following transfection. All the ligands were
dissolved in HBSS as well. Fluorescence intensity was measured by a FlexStation (Molecular
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Devices) at 480 nm for excitation and 525 nm for emission. All the ligands were also added by
FlexStation as well. For the luciferase complementation assay, cells expressing proteins of our
interest were trypsinized before the assay was carried out and were added into 96-well plate in
OPTI-MEM. NanoBit substrate was first added to cells before the addition of ligands.
Luminescence intensity was read by a FlexStation at 500 ms integration time.

2.7 Statistics
All the data were presented as mean ± standard error of mean (SEM). Statistical significance
between two groups was determined using unpaired t-test with an assumption of unequal
variance (Prism). For multiple groups of data, one-way ANOVA or two-way ANOVA was used
to assess significance followed by post hoc analysis (Prism). In the calcium mobilization assay,
Gi or Gs activities were determined by normalizing the drug-induced fluorescence to the basal
fluorescence level (peak value or area under the curve). In the NanoBit luciferase
complementation assay, arrestin recruitment was assessed by normalizing the drug-induced
luminescence to the basal luminescence level. In two-electrode voltage clamp experiments, Gi
and Gs activities were calculated by normalizing the drug-induced current to barium sensitive
HK-induced current. Dose-response curves were analyzed by non-linear regression to obtain
EC50 and Emax values using Prism.
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Chapter 3
Modulation of signaling of MOR by CB1R and CB1R ligands

3.1 Introduction

Clinical and animal behavior data suggest that cannabinoids (mainly delta 9 - THC) potentiate the
analgesic effects of opioids (Cichewicz DL et al. 1998). Furthermore, some research indicates that
cannabinoids decrease tolerance caused by morphine (Cichewicz DL et al. 2003). However, the
underlying molecular mechanisms for these effects remain unknown. Cannabinoids and opioids target
CB1R and MOR respectively, which signal through both G proteins and arrestin. G protein signaling is
responsible for the analgesic effects of opioids, while arrestin signaling mediates side effects, especially
tolerance (Manglik A et al 2016). In this study, we examine the effects of co-expression of the CB1R on
the Gi signaling of the MOR utilizing a calcium mobilization assay as well as two-electrode voltageclamp assay. We also investigated how CB1R modulates MOR arrestin recruitment utilizing the
NanoBit luciferase complementation assay.
Cannabinoid CB1R and MOR are Gi/o coupled receptors and their activation does not lead to calcium
mobilization. In order to ensure optimal coupling of CB1R and MOR to calcium mobilization to assay
their G protein signaling, we modified the Gα16 protein. Gα16 belongs to the Gαq superfamily and its
stimulation causes activation of phospholipase C (PLC) leading to calcium mobilization. Gα16 has been
reported to couple to some non-Gq coupled receptors such as 2-adrenergic receptors (Gs-coupled) as
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well as Muscarinic Type 2 receptor (M2R) (Gi-coupled), showing coupling promiscuity in mammalian
cell lines (Offermanns et al. 1995). Early work suggested that substitution of as few as the last three
amino acids of Gαq to Gαi enabled Gi/o-coupled receptors (Gi/oPCRs) to signal through the Gq
pathway (Conklin et al. 1993). Thus, replacement of the C-terminal end of the promiscuous Gα16
protein with those of Gαi/o or Gαs could couple most Gi/oPCRS and GsPCRs to calcium mobilization.
In some cases of GsPCRs, replacement of the α5 helix of Gα16 with Gαs sequence (~30 C-terminal
amino acids) enhances the coupling towards GsPCRs (Hazari et al. 2004). To sum up, the C-terminal
end, as far as including the 5 helix, of Gα proteins plays a critical role in receptor - G protein coupling
specificity. In order to quantify Gi activity of CB1R and MOR, a series of Gα16 chimeric proteins were
constructed. The C-terminal of Gα16 was replaced by the corresponding sequence of Gi/o or Gs
proteins.
In order to assess intracellular calcium level changes, a calcium sensor construct, GCaMP 6s was
used. GCaMP 6s is a fusion protein that links the calmodulin which senses intracellular calcium with an
enhanced version of the green fluorescent protein (GFP) (Chen TW et al. 2013). GCaMP 6s was coexpressed with GPCRs and Gα16 chimeras in cells to monitor calcium changes, once intracellular
calcium arises due to receptor activation, the conformational changes of eGFP will lead to increase in
fluorescence intensity. The calcium mobilization assay provides us a sensitive and robust way to
measure G protein activity.
We have also tested CB1R and MOR activity in the two-electrode voltage clamp assay given that
activation of G protein-sensitive inwardly rectifying K+ (GIRK) channels is the physiological target of
these GPCRs that mediates their analgesic effects (Ikeda et al. 2000). We utilized this physiological
GPCR target to couple to GIRK channels and accurately monitor Gi activity. Our lab has successfully
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characterized the signaling of the serotonin 2A – metabotropic glutamate type 2 receptor heteromer
using this method (Fribourg et al. 2011).
Arrestin recruitment, which mediates side effects of cannabinoids and opioids, was assessed by the
NanoBit luciferase complementation assay. NanoBit luciferase was split into two fragments (SmBit and
LgBit) which were used to tag the C-terminus of GPCRs and the N-terminus of the beta-arrestin2. We
set up this assay to explore how our GPCRs of interest recruit arrestin and how arrestin recruitment of
one receptor may be modulated by the other receptor.

3.2 Results
3.2.1 Homomeric MOR and CB1R Gi signaling through the calcium mobilization and TwoElectrode Voltage-Clamp assays
We first examined Gi signaling through homomeric CB1R and MOR. Figure 3.1 establishes the
calcium mobilization assay for Gi signaling through CB1R as well as MOR. Figure 3.1 A shows
representative fluorescence traces for HEK 293 cells that were co-transfected with CB1R, Gα16/o c11
chimera (with 11 C-terminal amino acids of Gαo replacing the corresponding residues of Gα16) and
GCaMP 6s. The fluorescence signal increased when 10 µM CP55,940 (CP), a cannabinoid agonist nonselective between CB1R and CB2R, was added to the cells but not Hank’s buffered salt solution (HBSS)
(vehicle). These results suggest that activation of CB1R leads to stimulation of the G16/o c11 chimera
resulting in calcium mobilization. Figure 3.1 B is a summary figure showing that cells only expressing
GCaMP 6s, GCaMP 6s with CB1R or GCaMP 6s with Gα16/o c11 do NOT exhibit calcium
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mobilization. Calcium mobilization was seen only when all three components were co-expressed
together giving a robust calcium signal upon receptor activation. Interestingly, we found that CB1R
could yield calcium mobilization when co-expressed with the “promiscuous” wild-type Gα16 protein.
We then proceeded to test co-expression of MOR, Gα16/o c11 chimera and GCaMP 6s in HEK 293
cells. As shown in Figure 3.1 C, application of 1 µM DAMGO, a selective MOR agonist, led to an
increase in fluorescence of GCaMP 6s due to receptor activation. Figure 3.1 D summarizes that coexpression of MOR, Gα16/o c11 chimera and GCaMP 6s mobilized intracellular calcium whereas
absence of any of the components did not. We have also utilized a construct that encodes the catalytic
domain of pertussis toxin (PTX), which specifically ADP-ribosylates the C-terminus of Gi/o subunits,
uncoupling them from the receptor. In Figure 3.1 D, the DAMGO-induced calcium mobilization was
significantly attenuated by co-expression of the catalytic domain of PTX, indicating Gi-mediated
signaling. Interestingly, we found that unlike CB1R, MOR does NOT couple to the “promiscuous”
Gα16 wild-type protein and that the G16/o c11 chimera is necessary and sufficient to couple this
receptor to calcium mobilization.
Utilizing this calcium mobilization assay, we proceeded to perform dose-response experiments.
Figure 3.2 A-C are dose-response curves of three different CB1R ligands. CP55,940 and WIN55,212-2
are commercially available cannabinoid agonists widely used in the cannabinoid research field. HEK
293 cells were transiently transfected with GCaMP 6s, CB1R and the Gα16/o c11 chimera. Both
CP55,940 and WIN55,212-2 exhibited calcium mobilization in a dose-response manner and gave
comparable Emax (within 20% of each other) but highly different EC50 values. These results suggest that
both CP55,940 and WIN55,212-2 are full agonists at the CB1R but they possess distinct potencies. We
have also constructed a dose-response curve for the CB1R inverse agonist SR141716 (also called
“Rimonabant”). SR141716 was co-applied with a maximally effective concentration, 10 µM CP55,940,
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and inhibited the activation effects of CP55,940 in a concentration dependent manner with an IC50 of
18.1nM. 100% Gi activity was calculated as the response caused by the saturating CP concentration of
10 µM. Next, we proceeded to construct dose-response curves for three MOR ligands. As shown in
Figure 3.2 D-F, three different MOR agonists, DAMGO, Morphine and TRV130 (also named
“Oliceridine”) activated MOR in a dose-dependent manner. The dose-response curves of these three
MOR agonists suggested that DAMGO is a full agonist, whereas Morphine and TRV130 are partial
agonists. We also showed that all the MOR agonists did not show any effects on CB1R.
Besides the calcium mobilization assay, we also utilized a second assay, namely the two-electrode
voltage clamp using Xenopus oocytes as a heterologous expression system (Hatcher-Solis et al. 2014).
We injected cRNAs encoding neuronal GIRK1/2 (G1/2) and CB1R or MOR. As shown in Figure 3.3,
oocytes expressing only CB1R did not show high potassium- (HK-) induced currents and oocytes
expressing only G1/2 showed HK-induced current which did not change when 1 µM WIN55,212-2 was
applied. However, when G1/2 was co-expressed with CB1R, there was a further increase in the inward
current when 1 µM WIN55,212-2 was added (Figure 3.3 C). Furthermore, the WIN-induced current
increase was abolished when the catalytic domain of PTX was co-expressed (Figure 3.3 D). Panel E
summarizes that application of 1 µM WIN55,212-2 induces significant increases in inward current when
both CB1R and GIRK1/2 are co-expressed (significance assessed through paired t-tests). Extracellular
barium ions (Ba2+) block GIRK1/2 currents and Panel E shows Ba2+-sensitive current. The results from
this electrophysiological assay suggest that CB1R signals to the GIRK1/2 channels via Gi proteins.

3.2.2 Effects of CB1R co-expression on Gi signaling of MOR
Following characterization of signaling through homomeric CB1R and MOR, we proceeded to test
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the effects of co-expression of CB1R on the Gi signaling through MOR. Different MOR : CB1R cDNA
ratios were transfected into HEK-293 cells to select relative ratios of the two receptors that achieve
maximal signaling difference. Figure 3.4 A, shows a significant increase in Gi signaling compared to
homomeric MOR signaling, when MOR and CB1R were co-expressed at a 1:2 cDNA transfection ratio.
The remaining receptor co-expression experiments all used this 1:2 ratio. In sum, we utilized a calcium
mobilization assay to show that non-stimulated CB1R potentiates Gi signaling through MOR.
Next, we performed dose-response experiments in which different DAMGO concentrations were
applied to cells either expressing MOR alone or co-expressing MOR and CB1R. As shown in Figure 3.4
B, we found that co-expression of CB1R produced a significant enhancement in the efficacy of
DAMGO (65%) with a smaller decrease in potency (25%). The efficacy was also plotted on the bar
graph shown on Panel C.
Besides the synthetic MOR agonist DAMGO, we also tested the clinically used drug, Morphine,
which is a partial agonist at MOR (Figure 3.2 E) in our calcium mobilization assay. We found that
similar to DAMGO, Morphine also induced a significantly higher response in cells co-expressing MOR
and CB1R than those expressing only MOR. This result suggests that the MOR signaling change can be
obtained in the absence of agonist just by co-expression of CB1R.
To corroborate these findings obtained in the calcium mobilization assay, we also tested whether coexpression of CB1R increases Gi signaling through MOR in the Xenopus oocyte heterologous
expression system. Consistent with the calcium mobilization assay, we found that DAMGO induced
significantly more current in oocytes co-expressing MOR and CB1R than in oocytes expressing only
MOR (Figure 3.4 D-E). Figure 3.4 F summarizes that DAMGO-induced Gi activity is enhanced by the
co-presence of CB1R when GIRK channel activity was used as the reporter of Gi signaling.
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To evaluate whether the effects of co-expression of CB1R on the Gi signaling through MOR is due to
heteromerization between MOR and CB1R, we used the strategy of co-expression of a mini-gene that
only encodes certain transmembrane (TM) domain of the receptor. Our computational models of these
receptors predict that TM5 of CB1R and MOR may be the interacting surface. We made two constructs
that encode CB1R TM5 and TM1 domain, respectively, with a N-terminal sequence of Somatostatin
receptor (SSTR3) to facilitate surface expression. Figure 3.5 A shows that co-expression CB1R TM5
and TM1 mini-gene does not affect the homomeric MOR or CB1R Gi signaling. Interestingly, we found
that co-expression of CB1R TM5 but not TM1 mini-gene abolished the Gi signaling increase through
MOR caused by co-expression of CB1R (Figure 3.5 B). This result suggests that the signaling change is
likely due to heteromerization of CB1R and MOR and TM5 of CB1R is likely the interaction surface of
the CB1R-MOR heteromer.

3.2.3 Effects of CB1R ligands on Gi signaling of MOR with CB1R co-expression
After evaluating the effects of co-expression of unliganded CB1R on the Gi signaling through MOR,
we sought to determine whether these effects could be altered further by co-application of CB1R
ligands. We first tested how the CB1R inverse agonist SR141716 modulates MOR Gi signaling. Figure
3.6 A shows that co-application of 10 µM SR141716 prevented the potentiated response to 10 µM
DAMGO exerted by CB1R co-expression with the MOR, essentially showing signaling not significantly
different from cells expressing only MOR. Next, we examined how the CB1R full agonists WIN55,2122 and CP55,940 modulated MOR Gi signaling. Since both CB1R and MOR are Gi coupled receptors,
we selected a dose (10 nM in this case) that did not activate the CB1R (based on the dose-response
curves of Figure 3.2). 10 nM WIN55,212-2 in combination with 10 µM DAMGO abolished the increase
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in Gi signaling, whereas co-application of 10 nM CP55,940 trended to enhance further the Gi signaling
caused by co-expression of CB1R (Figure 3.6 B-C; this further increase was not found to be statistically
significant when the significance was determined using one-way ANOVA followed by post-hoc tests).
These results demonstrate that addition of CB1R ligands further modulates the increase on MOR Gi
signaling caused by co-expression of the unliganded CB1R.
Given this functional crosstalk between MOR and CB1R, we proceeded to test a number of classic
cannabinoids (compounds structurally similar to THC) that were kindly provided by Dr. Makriyannis’
lab. Figure 3.7 shows the effects of these classical cannabinoid compounds at a concentration of 10 µM
each on the homomeric CB1R G protein signaling. We used CP55,940 as a reference compound and
determined the efficacy of all compounds relative to CP55,940. Nabilone (a clinically used anti-mimetic
drug), AM2304 (the most efficacious compound in the assay), AM841 (the compound used to obtain the
human CB1R crystal structure) and AM2389 were selected and dose-response experiments were
performed. Based on the dose-response curves, we selected a concentration that does not activate CB1R
Gi signaling and tested how this sub-threshold dose may modulate MOR signaling. As shown in Figure
3.7, 10 nM AM 2304 also tended to further potentiate the MOR Gi signaling similar to what CP55,940
did (again this further increase was not found to be statistically significant when the significance was
determined using one-way ANOVA followed by post-hoc tests, suggesting that perhaps higher
concentrations of the CB1R ligand might be more effective).

3.2.4 Homomeric MOR and CB1R arrestin recruitment in NanoBiT luciferase complementation
assay
Following the evaluation of the effect of CB1R and its ligands on MOR G protein signaling, we
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proceeded to examine effects of CB1R and its ligands on arrestin recruitment. We utilized the NanoBit
luciferase complementation assay to assess arrestin recruitment. HEK 293 cells were transiently
transfected with CB1R tagged with the C-terminal Large fragment of luciferase (CB1-C-Lg) and betaarrestin2 tagged with the N-terminal Small fragment of luciferase (ARR-N-S). Figure 3.8, Panel A,
shows luminescence signals upon addition of substrate (furimazine) indicating the level of intact
luciferase (LgBit and SmBit basally associating). Following addition of a GPCR ligand, recruitment of
arrestin to the GPCR would yield greater association of the two luciferase fragments and thus a measure
of ligand-stimulated arrestin recruitment. Addition of 10 µM WIN55,212-2 led to an increase in
luminescence whereas addition of the DMSO vehicle did not have an effect. A combination of 10 µM
WIN55,212-2 and 10 µM SR141716 application did not induce any change in luminescence. Figure 3.8
B summarizes the peak value over the basal luminescence signal (before addition of the ligand). 10 µM
WIN55,212-2 caused approximately a 7-fold increase whereas DMSO or co-application of WIN and SR
did not lead to significant changes. This result indicates that the CB1R full agonist WIN55,212-2 causes
CB1R activation and beta-arrestin2 recruitment. This effect is CB1R mediated since it could be
abolished by co-application of the CB1R inverse agonist SR141716. Figure 3.8 C-D, we performed
similar experiments testing another CB1R full agonist CP55,940. Addition of 10 µM CP55,940
increased luminescence, while DMSO or co-application of CP55,940 and SR141716 did not. Panel D
summarizes that CP55,940 induced more than a 2-fold increase in luminescence and DMSO addition or
co-application of CP55,940 and SR141716 did not.
After establishing the method for evaluating CB1R arrestin recruitment, we proceeded and sought out
to determine how MOR interacts with arrestin. C-terminal tagging of MOR with the small fragment of
luciferase (MOR-C-S) and the N-terminal tagging of beta-arrestin2 with the large fragment (ARR-N-Lg)
yielded the largest luminescence signals upon agonist application. Figure 3.9 A-B shows addition of
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luciferase substrate to HEK293 cells expressing MOR-C-S and ARR-N-Lg at 30 s, followed by addition
of the MOR agonist DAMGO at 300 s. Addition of substrate induced basal luminescence, while
application of DAMGO further increased the luminescence intensity. In contrast, application of OPTIMEM without DAMGO did not induce any change suggesting that DAMGO activation of MOR leads
into beta-arrestin recruitment. In Panel B, co-expression of G protein Receptor Kinase 2 (GRK2), which
is activated by Gβγ and phosphorylates the receptor to recruit arrestin, showed much greater increase in
luminescence as well as faster kinetics in reaching the peak luminescence upon agonist application. To
further validate our MOR-arrestin assay, we also tested TRV130, a “biased” MOR ligand (“Biased”
means the compound only signals to G protein but not to the beta-arrestin pathway) (Schmid CL et al.
2017). We found that unlike DAMGO, 10 µM TRV130 did not induce any change in luminescence
intensity (Figure 3.9 C), whereas TRV130 behaved as a partial MOR agonist in our calcium
mobilization assay.

3.2.5 Effects of CB1R co-expression on arrestin recruitment to MOR
After setting up the assay to detect arrestin recruitment for homomeric CB1R and MOR, we next
examined whether co-expression of CB1R could modulate MOR signaling to arrestins. In Figure 3.10
A-B, we showed that cells expressing MOR-C-S, ARR-N-Lg and untagged CB1R display less
DAMGO-induced luminescence increase than cells only expressing MOR-C-S and ARR-N-Lg in the
absence of GRK2. Panel B summarizes that co-expression of CB1R significantly decreased MOR betaarrestin recruitment. Figure 3.10 C-D shows that the mere presence of unliganded CB1R also suppressed
MOR arrestin recruitment in the presence of GRK2. In order to confirm that the effect was not ligand
specific, we also experimented with the clinically used drug, morphine. We have shown that 10 µM
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morphine also induces MOR recruitment of beta-arrestin as its application increased luminescence
levels. Importantly, morphine induced significantly less MOR recruitment of beta-arrestin with the coexpression of CB1R as shown in Figure 3.10 E-F.
Next we evaluated whether addition of CB1R ligands could further affect MOR arrestin
recruitment. In our experiments, only MOR and beta-arrestin are tagged with NanoBit luciferase
fragments but not CB1R, the luminescence increase only reflects MOR interaction with the beta-arrestin
protein. As shown in Figure 3.11 A-B, co-application of 10 µM DAMGO and 10 µM CP55,940 caused
significantly less enhancement in luminescence in cells co-expressing MOR and CB1R than in cells only
expressing MOR, suggesting that co-treatment with CP further decreased MOR arrestin recruitment.
However, very interestingly, we found that co-treatment with 10 µM WIN55,212-2 induces more betaarrestin recruitment in cells co-expressing MOR and CB1R, indicating that WIN55,212-2 co-treatment
with DAMGO increases MOR arrestin signaling (Figure 3.11 C-D). We have also tested one of our
classic cannabinoids, AM2304 and found that similar to CP55,940, AM2304 also further decreases
MOR arrestin recruitment.

3.3 Discussion

Opioids are the most effective analgesics in the clinic and are widely used albeit severe side effects
such as tolerance, respiratory depression, dependence and constipation. Cannabinoids have been shown
to enhance opioid analgesic effectiveness and reduce side effects. Studying the molecular mechanism of
MOR modulation by CB1R will facilitate development of novel therapeutics that may yield improved
analgesic effects with reduced side effects. In conclusion, our work has found that co-expression of
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CB1R enhanced the Gi signaling through MOR and depressed the recruitment of arrestin to MOR
(Figure 3.12) and these effects could be further accentuated by different CB1R ligands. The signaling
change is likely due to heteromerization of MOR and CB1R since it could be abolished by co-expression
of a CB1R transmembrane domain 5 (TM5) but not TM1 mini-gene.
Our study is the first to demonstrate that unliganded CB1R enhanced MOR Gi signaling.
Furthermore, addition of a sub-functional dose of CP55,940 could further increase Gi signaling whereas,
addition of the same dose of WIN55,212-2 (also non-functional) abolished the increase caused by CB1R
co-expression. Regarding the molecular mechanism into CB1R boosting MOR Gi signaling, there are
possibly two major explanations: (1) CB1R enhances MOR capability of mediating stronger Gi
signaling due to heteromerization; (2) MOR activation induces activation of CB1R and subsequently
causes an increase in Gi signaling. More work is needed to substantiate this observation. CP55,940 and
WIN55,212-2 behave similarly in homomeric CB1R Gi signaling (similar efficacy) although CP55,940
is more potent than WIN55,212-2 (Figure 3.2 A-C). It is noteworthy that CP55,940 and WIN55,212-2
act oppositely to MOR-CB1R heteromeric signaling. Our data showing that 10nM WIN inhibits MORCB1R heteromer signaling is consistent with results from Devi’s lab (Rios et al. 2006). Since the EC50
values of the two ligands are different (CP: 164 nM; WIN: 2.6 µM), the opposite result could be caused
by different occupation of the receptor given that 10nM was used for both drugs. Apart from different
occupancy at CB1R, it is also possible that WIN55,212-2 and CP55,940 have different binding sites at
CB1R which may also account for the opposite effects on the MOR-CB1R signaling.
We are also the first to show that MOR arrestin recruitment can by modulated by CB1R and its
ligands. Again, the mechanism underlying this phenomenon is unknown. It is not likely that CB1R
constitutive activity takes available beta-arrestin from MOR since co-expression of CB1R does not
change the basal luminescence intensity (luminescence intensity before the addition of agonist) (data not
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shown). The possible explanation is that the heteromerization of MOR-CB1R prevents MOR interaction
with the arrestin protein. GRK2 phosphorylation at MOR is required to recruit beta-arrestin to the
receptor (Arttamangkul et al. 2018), which is supported by our data showing different kinetics and
amplitudes in luminescence change in the presence and absence of GRK2. TRV130, a biased ligand,
does not cause MOR recruiting beta-arrestin even when GRK2 is over-expressed. Morphine is a partial
agonist at MOR in both G protein and arrestin signaling according to the literature and our data are
consistent with this conclusion. We barely detected morphine induced MOR arrestin recruitment in the
absence of GRK2 and the signaling in the presence of GRK2 is much less than DAMGO (Morphine:
around 1.6 fold; DAMGO: around 6 fold). Overall, we demonstrate that the CB1R potentiates Gi
signaling of MOR while it inhibits the arrestin recruitment to MOR and these findings motivate us to
screen CB1R ligands to identify ones that maximize the Gi signaling while minimizing the arrestin
signaling.
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Figure 3.1 Gi signaling through the CB1R and MOR using calcium mobilization assay. AC,
Representative traces of Gi signaling from CB1R and MOR. BD, Quantitative data of normalized
fluorescence. HEK 293 cells were transiently transfected with 30ng GCaMP 6s (GCaMP), 50ng CB1R
or MOR and (with or without) 50ng G proteins per well with lipofectamine 2000. Intracellular calcium
levels were detected by a FlexStation, 48 hours after transfection. Peak value of fluorescence after
compound application over the basal value was plotted as normalized fluorescence. Quantitative data of
n = 5 - 8 experiments (Mean± SEM) are shown. Significance was determined using one-way ANOVA
(* p<0.05; ** p<0.01 ).
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Figure 3.2. Dose-response curves for CB1R and MOR ligands using calcium mobilization assay.
HEK 293 cells were transiently transfected with 30ng GCaMP 6s (GCaMP), 50ng CB1R or MOR and
(with or without) 50ng G proteins per well with lipofectamine 2000. Intracellular calcium levels were
detected by a FlexStation, 48 hours after transfection. 100% Gi activity on CB1R and MOR was defined
as maximum effects of CP55,940 and DAMGO, respectively. Quantitative data of n = 5 - 8 experiments
(Mean± SEM) are shown.

EC50 = 164.3 nM

IC50 = 18.1 nM

EC50 = 2.6 uM

Emax = 100

Emax = 121.4

DAMGO: [D-Ala2-N-MePhe4,Gly-ol5]-enkephalin
EC50 = 208 nM
EMAX = 100

EC50 = 519 nM
Emax = 47.01
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EC50 = 28 nM
Emax = 26.48

Figure 3.3 Gi signaling through the CB1 receptor using GIRK1/2 as reporter. A-D. The
representative trace of the Gi signaling from homomeric CB1 receptors (injection conditions are shown
at the top of each figure). E. Summary data of the Gi signaling from homomeric CB1 receptors. Oocytes
were injected with 1ng G1, G2, CB1R and PTX cRNA. The concentration of WIN55,212-2 (WIN) and
Ba2+ is 1μM and 3mM, respectively. Quantitative data of n = 4 - 6 experiments (Mean± SEM) are
shown. Significance was determined using two-way ANOVA followed by post-hoc test (** p<0.01 ).
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Figure 3.4 Co-expression of CB1R increases Gi signaling through the MOR A. Effects of coexpression of different amount of CB1R on Gi signaling through the MOR. B. Dose-response curves of
DAMGO in HEK 293 cells expressing MOR or MOR and CB1R. C. Summary data of the Gi signaling
from MOR in HEK 293 system. D-E. The representative current traces of the Gi signaling from MOR in
the absence and presence of CB1R in oocyte system (injection conditions are shown at the bottom of
each figure). F. Summary data of the Gi signaling from MOR in oocyte system. Oocytes were injected
with 1ng G1, G2, MOR and 2ng CB1R cRNA. MOR response upon CB1R co-expression
(MOR:CB1R=1:2) was normalized to homomeric MOR response (homomeric MOR response is 1).
Quantitative data of n = 6-10 experiments (Mean± SEM) are shown. Significance was determined using
student T test (** p<0.01 ).
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Figure 3.5 Co-expression of CB1R transmembrane domain 5 (TM5) but not TM1 mini-gene
abolishes Gi signaling increase through MOR with CB1R co-expression without affecting
homomeric receptor signaling. A. Effects of co-expression of CB1R TM1 and TM5 mini-gene on Gi
signaling through homomeric CB1R and MOR. HEK 293 cells were transiently transfected with 30ng
GCaMP 6s, 50ng CB1R or MOR, 50ng G16/o with or without 50ng CB1R TM5 or TM1 per well. 10uM
DAMGO was used on cells expressing MOR and 10uM CP55,940 was used on cells expressing CB1R.
B. Effects of co-expression of CB1R TM1 and TM5 mini-gene on Gi signaling through heteromeric
CB1R-MOR. HEK 293 cells were transiently transfected with 30ng GCaMP 6s, 25ng MOR, 50ng
G16/o with or without 50ng CB1R or CB1R TM5 or TM1 per well. 10uM DAMGO was applied to the
cells. 100% Gi activity was defined as homomeric MOR response to 10uM DAMGO. Quantitative data
of n = 5 - 8 experiments (Mean± SEM) are shown. Significance was determined using one-way
ANOVA followed by post hoc tests (* p<0.05; ** p<0.01 ).
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Figure 3.6 CB1R ligands modulate Gi signaling through the MOR with CB1R co-expression. A-C.
Effects of SR141716, WIN55,212-2 and CP55,940 on Gi signaling through MOR with CB1R coexpression. HEK 293 cells were transiently transfected with 30ng GCaMP 6s, 50ng CB1R, 25ng MOR
and 50ng G16/o. 100% Gi activity was defined as homomeric MOR response to 10uM DAMGO.
Quantitative data of n = 5 - 8 experiments (Mean± SEM) are shown. Significance was determined using
one-way ANOVA followed by post-hoc tests (* p<0.05; ** p<0.01 ).
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Figure 3.7 Classical cannabinoids modulate Gi signaling through the MOR with CB1R coexpression A. Screening of classical cannabinoids. All the compounds were dissolved at 10 µM. The
response was normalized to the maximum effects of CP55,940(10uM CP’s effect is 1). B,C. Doseresponse curves for Nabilone, AM2304, AM841 and AM2389. HEK 293 cells were transiently
transfected with 30ng GCaMP 6s (GCaMP), 50ng CB1R and 50ng G16/o c11 per well with
lipofectamine 2000. Intracellular calcium levels were detected by a FlexStation, 48 hours after
transfection.
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Figure 3.8 Beta-arrestin recruitment through the CB1R using NanoBit luciferase
complementation assay. A, C. Representative traces of luminescence upon different CB1R ligand
application. B, D. Summary data of beta-arrestin recruitment from CB1R. Peak value of luminescence
after compound application over the basal value was plotted as normalized luminescence. HEK 293 cells
transiently transfected with (CB1-C-Lg) and (ARR-N-S) with Lipofectamine 2000. Luminescence levels
were detected by a BMG plate reader, 28 hours after transfection. Quantitative data of n = 5 - 8
experiments (Mean± SEM) are shown. Significance was determined using one-way ANOVA followed
by post hoc tests (* p<0.05; ** p<0.01 ).
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Figure 3.9 Beta-arrestin recruitment through the MOR using NanoBit luciferase complementation
assay A-C. Representative traces of luminescence upon different MOR ligand application. HEK 293
cells transiently transfected with (MOR-C-S) and (ARR-N-Lg) with Lipofectamine 2000. Luminescence
levels were detected by a FlexStation, 28 hours after transfection.
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Figure 3.10 CB1R co-expression decreases arrestin recruitment to MOR A, C, E. Representative
traces of luminescence upon different MOR ligand application. B, D, F. Summary data of beta-arrestin
recruitment to MOR. Peak value of luminescence after compound application over the basal value was
plotted as normalized luminescence. HEK 293 cells transiently transfected with (MOR-C-S) and (ARRN-Lg) with or without CB1R using Lipofectamine 2000. Luminescence levels were detected by a
FlexStation, 28 hours after transfection. Quantitative data of n = 5 - 8 experiments (Mean± SEM) are
shown. Significance was determined using student T test (* p<0.05; ** p<0.01 ).
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Figure 3.11 CB1R ligands further modulate arrestin recruitment to MOR with CB1R coexpression. A, C. Representative traces of luminescence upon different MOR and CB1R ligand
application. B, D. Summary data of beta-arrestin recruitment to MOR. Peak value of luminescence after
compound application over the basal value was plotted as normalized luminescence. HEK 293 cells
transiently transfected with (MOR-C-S) and (ARR-N-Lg) with or without CB1R using Lipofectamine
2000. Luminescence levels were detected by a FlexStation, 28 hours after transfection. Quantitative data
of n = 5 - 8 experiments (Mean± SEM) are shown. Significance was determined using student T test (*
p<0.05; ** p<0.01 ).
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Figure 3.12 Summary of MOR-CB1R heteromer signaling MOR and CB1R can both signal to G
protein pathway that mediates analgesic effects and arrestin pathway mediating side effects. Coexpression of CB1R enhances the Gi signaling through MOR and depresses the arrestin recruitment to
MOR.
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Chapter 4

Modulation of signaling of CB1R by D2R

4.1 Introduction
Researchers have utilized co-immunoprecipitation (co-IP) and fluorescence resonance energy
transfer (FRET) to demonstrate the physical interaction between CB1R and D2R (Kearn et al
2005; Marcellino et al 2008). Interestingly, this CB1R-D2R interaction has exhibited unique
signaling properties. D2R and CB1R have been shown to be primarily Gi coupled receptors by a
number of different scientists (Beaulieu et al. 2015; Howlett et al 2017). However, Jarrahian et al
reported that in cells co-expressing CB1R and D2R, activation of CB1R by agonist CP55,940
(CP) led to an increase in cAMP level, indicating a possible Gs coupling of CB1R in the
presence of D2R (Jarrahian et al. 2004). Based on these findings, we aimed to answer the
question whether upon heteromerization D2R switches the CB1R coupling specificity from Gi to
Gs. We first examined the CB1R and D2R signaling in our Xenopus oocytes heterologous
expression system. Our electrophysiology assay provides direct evidence for Gi and Gs coupling
and it also allows us to control precise injection of GPCR cRNA ratios to optimize for maximal
heteromerization effects. We also confirmed our findings using a calcium mobilization assay.

4.2 Results

48

4.2.1 Homomeric CB1R and D2R Gi and Gs signaling in two-electrode voltage-clamp
assay
We first examined Gi signaling through homomeric CB1R and D2R. As was shown in Figure
3.3 and discussed in Chapter 3, application of the CB1R agonist WIN55,212-2 (1µM) caused
further increase in inwardly rectifying potassium current in oocytes co-expressing GIRK1/2 and
CB1R. The WIN-induced current increase could be abolished by the co-expression of the
catalytic domain of pertussis toxin (PTX), suggesting that CB1R signals to GIRK1/2 through
PTX sensitive Gi/o proteins. Similarly, D2R also showed Gi/o signaling in our two-electrode
voltage-clamp assay. Figure 4.1 A and B are negative controls showing that dopamine does not
directly activate GIRK 1/2 channels. Panel C shows that 1µM dopamine (the endogenous D2R
agonist) further enhanced the inward potassium current in oocytes co-expressing GIRK1/2 and
D2R. Co-expression of the catalytic domain of PTX abolished the dopamine-induced current
enhancement (Figure 4.1 D). Panel E summarizes the barium sensitive current, showing that
dopamine activates D2R and signaling to GIRK1/2 through PTX-sensitive Gi/o proteins.
We next set up an assay to monitor Gs protein signaling in our two-electrode voltage clamp
assay. Lim et al. first showed that a Gs-coupled receptor (beta2-adrenergic receptor) can signal
to GIRK channels in an oocyte system via Gβγ subunits only if the Gαs subunit is overexpressed
(Lim et al 1995). As shown in Figure 4.2 A-B, we co-expressed GIRK1/2 with the beta2adrenergic receptor (Beta2R), Gαs and the PTX A-protomer in oocytes. Application of 1 µM
isoproterenol (ISO), a Beta2R agonist, caused a significant PTX-insensitive increase in inward
potassium current, consistent with the Lim et al. finding. We have also tested another Gs-coupled
receptor, adenosine 2A receptor (A2AR). CGS21680 (CGS), a synthetic A2AR full agonist,
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could stimulate the A2AR leading to PTX-insensitive activation of GIRK1/2 current through Gs
signaling (Figure 4.2 C-D).
After setting up the assay to monitor receptor Gs signaling using GIRK1/2 as a reporter in the
oocyte heterologous expression system, we sought to examine whether homomers of CB1R or
D2R could signal via the Gs pathway. Figure 4.3 A shows that activation of CB1R by 1µM
WIN55,212-2 did not further increase GIRK current. Panel B summarizes that 1µM WIN
induced GIRK channel activation in oocytes only expressing GIRK1/2 and CB1R but not in
oocytes co-expressing with PTX or PTX and Gαs, indicating that homomeric CB1R can only
signal through the Gi/o pathway but not through the Gs pathway. Similarly, as shown in Figure
4.3 C-D, D2R in homomeric form could only signal through the Gi pathway but not through the
Gs pathway.

4.2.2 Homomeric CB1R and D2R Gi and Gs signaling in calcium mobilization assay
Besides using an electrophysiological assay, we also utilized a calcium mobilization assay to
further validate the results obtained in oocytes. We used Gα16 chimeras to monitor Gi and Gs
activity. As introduced in Chapter 3, replacement of the C-terminus of the promiscuous Gα16
with the corresponding sequence of Gαi/o or Gαs enables coupling to most Gi/oPCRs and
GsPCRs (that do not already couple to the promiscuous Gα16 wild-type protein) to mobilize
intracellular calcium. Glucagon receptor (GCGR), a Gs-coupled receptor, served as a positive
control for monitoring Gs activity using Gα16/s chimeras. In Figure 4.4, HEK293 cells were cotransfected with GCaMP 6s, GCGR with or without Gα16WT or chimeras to perform doseresponse experiments. Cells only expressing GCGR showed almost no calcium mobilization
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signaling, whereas cells co-expressing GCGR and wild-type Gα16 (G16wt) protein mobilized
intracellular calcium upon application of GCGR endogenous ligand Glucagon, suggesting that
GCGR could couple to the promiscuous wild-type Gα16. Interesting, cells co-transfected with
GCGR and Gα16/s chimeras (either 11 or 30 amino acids at the very C-terminal end of Gα16
were replaced with those of Gαs) showed a left-shift in the dose-response curve (EC50 value) as
well as greater maximal effect of glucagon (efficacy) compared to cells co-transfected with
GCGR and G16wt (Figure 4.4). These results suggest that co-expression of Gα16/s chimeras
with GPCR serves as a suitable method to assess receptor Gs signaling. Next, we proceeded to
explore how CB1R and D2R signal to Gi and Gs in homomeric forms using this method. In
Figure 4.5 A, cells co-expressing CB1R and Gα16/o chimera (G16/o c11) gave a robust increase
in fluorescence upon application of 10 µM WIN55,212-2, whereas, co-expression of CB1R and
Gα16/s chimera (G16/s c30) gave much less increase, indicating that homomeric CB1R signals
primarily towards the Gi/o pathway. Similarly in the case of D2R, D2R coupled very well with
G16/o c11 but not with G16/s c30 (Figure 4.5 B). In conclusion, these results in mammalian cells
using the calcium mobilization assay show that both CB1R and D2R are primarily Gi/o coupled,
results consistent with those in oocytes using electrophysiology and GIRK channels as reporters
of GPCR signaling.

4.2.3 Effects of co-expression of D2R on signaling through CB1R
After setting up assays for both Gi and Gs signaling pathway, we proceeded to examine the
effects of co-expression D2R on signaling through CB1R. In Figure 4.6 A, oocytes injected with
cRNA encoding GIRK1/2, CB1R, PTX and Gs, showed high potassium- (HK-) induced current
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and addition of 1µM WIN55,212-2 did not cause further channel activation, indicating no Gs
signaling through homomeric CB1R. In contrast, 1µM WIN55,212-2 application led to a further
increase in GIRK current in oocytes co-expressing GIRK1/2, CB1R, PTX , Gs and D2R (ratios
of D2R/CB1R at 2 and 3), but 1µM dopamine did not signal through Gs (Figure 4.6 B-C). In
panel D, we summarized the WIN-induced GIRK current (current after WIN application minus
HK-induced current) and found that co-expression of D2R (at ratio D2R/CB1R of 3) showed
significantly larger WIN-induced GIRK current, suggesting that co-expression of D2R enables
CB1R signaling towards Gs signaling pathway in our electrophysiology assay. We also
confirmed these findings in the calcium mobilization assay. In Figure 4.7, co-expression of D2R
(at a ratio D2R/CB1R of 4 but not 2) significantly increased the fluorescence enhancement upon
stimulation with the CB1R agonist WIN55,212-2 in HEK293 cells co-expressing receptors and
G16/s c30, suggesting that D2R co-expression enhances CB1R Gs signaling.

4.3 Discussion
In conclusion, we utilized both electrophysiology assay and calcium mobilization assay to
show that D2R co-expression switches the coupling specificity of CB1R from Gi to Gs signaling
pathway. As demonstrated in Figure 4.8, both CB1R and D2R are primarily Gi-coupled receptors
upon activation by their corresponding agonists, however, co-expression of D2R switches CB1R
towards a Gs-coupled pathway while D2R maintains its Gi signaling specificity. Whether this
signaling switching is due to heteromerization of CB1R and D2R remains unknown. One
possible way to test this hypothesis to see whether the signaling switch of CB1R caused by coexpression of D2R can be abolished by D2R transmembrane domain peptide treatment or minigene co-expression.
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We are the first to provide direct evidence that CB1R interacts with Gs and activates GIRK
channels in our oocytes heterologous expression system. Our results explained the reason why
CB1R activation increases cAMP level in HEK 293 cells expressing both CB1R and D2R. We
are also the first group to use G16 chimeras to study G protein coupling specificity switch. Given
that C-terminal end and α5 Helix are critical in interacting with receptor, our G16 chimeras serve
as a great tool to study receptor – G protein interaction, although G16 chimeras are artificial
proteins and do not completely represent the function of the original Gαi/o and Gαs proteins.
Interestingly, our results with G16 chimeras correlate well with our findings in oocyte
heterologous expression system, indicating that the calcium mobilization assay using Gα16
chimeras provides a novel method to study receptor – G protein interaction.
We do not fully understand the physiological roles of the coupling specificity switch of CB1R.
Receptors may need to expand their signaling pathways through different mechanisms such as
receptor heteromerization. The physiological consequence of CB1R switching to a Gs coupled
receptor remains a mystery. What also remains unknown is the regulatory mechanism of
heteromeric CB1R-D2R complex formation, e.g. does chronic CB1R agonist treatment affect the
level of CB1R heteromer over homomers. It will also be interesting to examine whether CB1R
beta-arrestin recruitment can be affected by heteromerization with D2R since CB1R interaction
with beta-arrestin mediates drug-induced tolerance.

53

Figure 4.1 Gi signaling through the D2 receptor using GIRK1/2 as reporter. A-D. The
representative trace of the Gi signaling from homomeric D2R (injection conditions are shown at
the top of each figure). E. Summary data of the Gi signaling from homomeric D2 receptors.
Oocytes were injected with 1ng G1, G2, D2R and PTX cRNA. The concentration of dopamine
(DA) and Ba2+ is 1μM and 3mM, respectively. Quantitative data of n = 5 - 6 experiments (Mean
± SEM) are shown. Significance was determined using two-way ANOVA (** p<0.01 ).
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Figure 4.2 Gs signaling through the Beta2R and A2AR using GIRK1/2 as reporter. A,C.
The representative trace of the Gs signaling from homomeric Beta2R and A2AR. B,D. Summary
data of the Gs signaling from homomeric Beta2R and A2AR. Oocytes were injected with 1ng
G1, G2, Beta2R, A2AR, Gs and PTX cRNA. The concentration of isoproterenol (ISO),
CGS21680 (CGS) and Ba2+ is 1μM, 1μM and 3mM, respectively. Quantitative data of n = 5 - 6
experiments (Mean±SEM) are shown.
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Figure 4.3 No Gs signaling through the homomeric CB1R or D2R using GIRK1/2 as
reporter. A,C. The representative trace of oocytes expressing G1, G2, PTX, Gs, CB1R or D2R.
B,D. Summary data of the Gs signaling from homomeric CB1R and D2R. Oocytes were injected
with 1ng G1, G2, CB1R, D2R, Gs and PTX cRNA. The concentration of WIN55,212-2 (WIN),
dopamine (DA) and Ba2+ is 1μM, 1μM and 3mM, respectively. Quantitative data of n = 5 - 6
experiments (Mean±SEM) are shown. Significance was determined using two-way ANOVA (*
p<0.05; ** p<0.01 ).
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Figure 4.4 Gs signgaling through the glucagon receptor (GCGR) using calcium
mobilization assay. HEK 293 cells were transiently transfected with 30ng GCaMP 6s (GCaMP),
50ng GCGR and (with or without) 50ng G proteins per well with lipofectamine 2000.
BIntracellular calcium levels were detected by a FlexStation, 48 hours after transfection. Peak
value of fluorescence after compound application over the basal value was plotted as normalized
fluorescence. Quantitative data of n = 4 - 6 experiments (Mean±SEM) are shown.
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Figure 4.5 Gi and Gs signaling through the homomeric CB1R and D2R using calcium
mobilization assay. A. HEK 293 cells were transiently transfected with 30ng GCaMP 6s
(GCaMP), 50ng CB1R and 50ng G proteins per well with lipofectamine 2000. B. HEK 293 cells
were transiently transfected with 30ng GCaMP 6s (GCaMP), 50ng D2R and 50ng G proteins per
well with lipofectamine 2000. Intracellular calcium levels were detected by a FlexStation, 48
hours after transfection. Peak value of fluorescence after compound application over the basal
value was plotted as normalized fluorescence. Quantitative data of n = 4 - 6 experiments
(Mean±SEM) are shown.
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Figure 4.6 Gs signaling through the CB1R upon co-expression of D2R using GIRK1/2 as
reporter. A-C. Representative traces of CB1R signaling upon co-expression of D2R (injection
conditions are shown at the top of each figure). The concentration of WIN55,212-2 (WIN),
dopamine (DA) and Ba2+ is 1μM, 1μM and 3mM, respectively. D. Summary data of the Gs
signaling from heteromeric CB1R-D2R complex. WIN-induced GIRK current was plotted. Data
of n = 5 - 8 experiments (Mean±SEM) are shown. Significance was determined using one-way
ANOVA followed by post-hoc tests (**p<0.01 ).
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Figure 4.7 Gs signaling through the CB1R upon co-expression of D2R using calcium
mobilization assay. A. HEK 293 cells were transiently transfected with 30ng GCaMP 6s
(GCaMP), 50ng CB1R, 25ng or 12.5ng D2R and 50ng G proteins per well with lipofectamine
2000. Peak value of fluorescence after compound application over the basal value was plotted as
normalized fluorescence. B. CB1R response upon D2R co-expression (ratio of CB1R:D2R=4:1)
was normalized to homomeric CB1R response (homomeric CB1R response is 1). Significance
was determined using student T test (* p<0.05 ).
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Figure 4.8 D2R switches the signaling specificity of CB1R. CB1R and D2R homomeric
forms are primarily Gi coupled upon agonist activation. CB1R switches its signaling specificity
from Gi-coupled to Gs coupled upon co-expression of D2R.
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Chapter 5

Concluding remarks

We investigated CB1R-MOR and CB1R-D2R interactions utilizing a calcium mobilization
assay, an electrophysiology assay and the NanoBit luciferase complementation assay. Our
calcium mobilization assay is widely used in both academia and industry, providing a sensitive
and robust way to measure G protein activity. Our two-electrode voltage-clamp assay using
GIRK channels as reporter gives a membrane-delimited readout of G protein activity. Both
systems allow us to titrate receptor expression to achieve maximal signaling difference. In our
studies, results from these two assays are in strong agreement. The NanoBit luciferase
complementation assay provides us an accurate method to assess arrestin recruitment to
receptors.
In Chapter 3, we focused on the modulation of signaling of MOR by CB1R and its ligands.
Our data demonstrate the unliganded CB1R enhances MOR Gi signaling while depresses arrestin
recruitment to MOR and these effects showed the potential to be further accentuated by various
CB1R ligands at sub-threshold stimulatory concentrations. The signaling change is possibly
caused by CB1R-MOR heteromerization since it could be abolished by co-expression of CB1R
TM5 but not TM1 mini-gene. Our findings motivate us to further identify CB1R ligands that
maximize Gi signaling while minimizing arrestin recruitment to facilitate development of novel
therapeutics that may yield improved analgesic effects with reduced side effects.
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Chapter 4 focused on studying the modulation of CB1R by D2R. Utilizing a calcium
mobilization assay with a two-electrode voltage-clamp assay, we demonstrated that D2R coexpression switches the coupling specificity of CB1R from Gi to Gs signaling pathway. The
physiological consequence of CB1R switching to a Gs coupled receptor requires further
research.
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